Morphine-6-glucuronide: An analgesic of the future?

Clinical Pharmacokinetics

Volumn 40, Issue 7, 2001, Pages 485-499

  Lötsch, Jörn ^a   Geisslinger, Gerd ^a  

^a GOETHE UNIVERSITY   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ANALGESIC AGENT; MORPHINE; MORPHINE 6 GLUCURONIDE; OPIATE RECEPTOR;

ANALGESIA; BLOOD BRAIN BARRIER; CLINICAL TRIAL; DRUG BLOOD LEVEL; DRUG EFFECT; DRUG HALF LIFE; DRUG INDUCED DISEASE; DRUG METABOLISM; DRUG POTENCY; DRUG TOLERABILITY; GASTROINTESTINAL SYMPTOM; HUMAN; KIDNEY CLEARANCE; KIDNEY FUNCTION; POSTOPERATIVE ANALGESIA; PRIORITY JOURNAL; RECEPTOR AFFINITY; RESPIRATION DEPRESSION; REVIEW;

EID: 0034896025     PISSN: 03125963     EISSN: None     Source Type: Journal    
DOI: 10.2165/00003088-200140070-00001     Document Type: Review

References (5)

1. Hasselström J, Alexander N, Bringel C, et al. Single-dose and steady-state kinetics of morphine and its metabolites in cancer patients: a comparison of two oral formulations. Eur J Clin Pharmacol 1991; 40: 585-91
2. Kamata O, Watanabe S, Ishii S, et al. Analgesic effect of morphine glucuronides. Proceedings of the 89th Meeting Pharmacology Society of Japan; 1969: 443
3. Tiseo PJ, Thaler HT, Lapin J, et al. Morphine-6-glucuronide concentrations and opioid-related side effects: a survey in cancer patients. Pain 1995; 61: 47-54
4. Hanna MH, Peat SJ, Woodham M, et al. Analgesic efficacy and CSF pharmacokinetics of intrathecal morphine-6-glucuronide: comparison with morphine. Br J Anaesth 1990; 64: 547-50
5. Peat SJ, Hanna MH, Durcan M, et al. Morphine-6-glucuronide in post operative pain [abstract]. Proceedings of the 9th World Congress of Pain; 1999 Aug 22-27; Veinna. Seattle (WA): International Association for the Study of Pain, 2000: 334-5